Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...
Roche’s Xofluza reduces flu transmission in Phase 3 study
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in ...
GlobalData on MSN3d
Roche reports positive data from Phase III influenza treatment trial
According to the findings, the antiviral treatment demonstrated to significantly reduce the transmission of influenza viruses ...
Roche unit hits main goal in late-stage trial for flu therapy
Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its ...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to ...
Pharmabiz2d
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...
The Pharma Letter3d
Roche touts positive Phase III results with Xofluza
Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...
Business Wire3d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...
Nasdaq3d
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
(RTTNews) - Roche's (RHHBY) Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE study. The results demonstrated that a single oral ...
Morningstar3d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – – This is the first time that any antiviral used in ...